Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 2/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956695 | 0.77 | MAOB (0.51) | SMN1; SMN2ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL23220318 | 0.75 | IDO1 (0.68) | SMN1; SMN2ALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL3192546 | 0.75 | SRD5A2 (0.58) | SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL6154909 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| Alcohol SCHEMBL28252000 | 0.74 | KMT2A (0.62) | SMN1; SMN2ALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL6242743 | 0.74 | FFAR1 (0.53) | SMN1; SMN2ALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL31657190 | 0.74 | AKR1C3 (0.62) | ALDH1A1KMT2ARAB9A | |
| SCHEMBL5213552 | 0.71 | SLC7A5 (0.55) | SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL4959727 | 0.71 | MAPT (0.55) | SMN1; SMN2ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL7558146 | 0.71 | KMT2A (0.56) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | SMN1; SMN2 2211/4885CRHBP 3560/4885CRHR2 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.